# Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

> **NCT03539822** · PHASE1,PHASE2 · RECRUITING · sponsor: **Anwaar Saeed** · enrollment: 117 (estimated)

## Conditions studied

- Gastric Cancer
- Esophageal Adenocarcinoma
- Hepatocellular Carcinoma
- Colorectal Cancer

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03539822
- **Lead sponsor:** Anwaar Saeed
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-10-22
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03539822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03539822, "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03539822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*